Introduction
Will manipulations of dialytic therapy have any real Dialysis support for the critically-ill patient with acute effect on the devastatingly poor outcome of the renal failure (ARF ) is now under scrutiny [1], but condition? despite the increasing attention many crucial questions
The consistently high mortality of ICU ARF over remain unanswered. In this article, we examine some the years hides the worsening face of the patient of the reasons for these ambiguities and discuss poten-population [10] , suggesting that we are gaining ground tial solutions.
overall. Although the kidney is usually but one of several failing organs in this setting, ARF contributes disproportionately to mortality [11, 12] and leads to an
The problems increased risk of developing 'non-renal' complications such as bleeding and sepsis [11] . Of encouragement is The ESRF-ARF interface the finding that increasing membrane biocompatibility significantly improves rates of renal recovery [13] and Certain well-defined standards of dialysis support for reduces rates of lethal sepsis [14] , highlighting the the patient with end-stage renal failure ( ESRF ) have potential impact of dialytic manipulations. Van become basic tenets of nephrological practice [2] . Any Bommel and co-workers found the ratio of APACHE suggestion of establishing similar standards in critical II at the time of dialysis initiation to that at ICU care dialysis is obviously premature, but can we gener-admission (AP 2 /AP 1 ) to be highly predictive of death, alize from our experience in ESRF?
suggesting that irreversible derangements prior to diaUnfortunately, a number of crucial factors within lysis initiation were still (probably most) important the two, quite distinct populations, make extrapola- [15] . Whether these derangements were a consequence tions problematic.
of ARF or its precursors is not clear but Levy's work Firstly, the pace of change in the intensive care unit [11] would point towards the first mechanism. (ICU ) ARF population is very different; critical endpoints are reached in days-to-weeks as opposed to the attrition that we are used to of months-to-years in Choice of modality ESRF patients, so dialysis efficacy will have to be Intuitively, continuous renal replacement therapy judged within a very much shorter time-frame.
(CRRT ) is seen as the modality of choice, with sugSecondly, those end-points that concern us may be gested advantages including haemodynamic stability quite different in the two groups-renal recovery and (enhancing fluid removal and hyperalimentation), length of ICU stay [3] as opposed to hypertensive improved dialysis dose delivery, enhanced removal of control [4], for instance. Lastly, the negligible impact inflammatory mediators and an improvement in overall of G, the urea generation rate, and the predictability outcome. Recent experience [16, 17] , however, warns of V urea , the volume of distribution of urea, are assumpagainst taking for granted these perceived notions of tions made to implement formal urea kinetic modelling therapeutic superiority in the absence of a good, evid-( UKM ) in ESRF [5] . Clearly, this may not be the ence base. case in critically ill ARF patients with the potential We will examine each of these potential advantages for marked hypercatabolism [6] [7] [8] and large variations in turn but it is worth noting that in Jakob's extensive in V urea [9], with major implications when considering review [18] of all 67 published studies dealing with delivered dialysis dose (see later).
CRRT that were available to them at that time (1996), only 15 were comparative. In only three of these Correspondence and offprint requests to: Dr N. S. Kanagasundaram, [19] [20] [21] were both modality groups studied prospect-numbers hampered many studies. Incomplete descrip-changes in pressor doses or of the timing of pre-and post-therapy blood pressure readings was provided. tions of both patient populations and dialysis therapy were widespread. In the 12 studies in whom filter type Hypotension may, of itself, be limited to the intradialytic period [27] although this may not be without its was recorded, none applied the same filter across modalities-biocompatible membranes tended to be longer term implications for renal recovery [30] . The development of supplementary techniques such as used in CRRT and bioincompatible membranes in intermittent therapies (a difference that we know can sodium and ultrafiltration profiling, and on-line optical haematocrit monitoring, may further enhance tolerimpact upon outcome [13, 14] ). Two of the 15 comparative studies [22, 23] used a 'conventional dialysis' ability of intermittent therapy [31] The delivered dialysis dose has been shown to impact upon patient outcome, at least in certain subgroups: therapies although concrete data to support this assertion is rather scanty. using retrospective data, dose seemed to have no effect at either end of the disease severity spectrum but, in Although it has been shown that haemodialysisresistant fluid overload in ARF responds well to SCUF, those with intermediate severity scores, an URR (urea reduction ratio) of >58% in IHD and a TAC urea (time allowing enhanced nutrition and drug delivery [24] , and that fluid removal by continuous arteriovenous averaged concentration of urea) of <45 mg/dl in CRRT were both associated with significant reductions haemofiltration (CAVH ) improves the cardiac index [25] , data from more rigorous, comparative studies in mortality [32] . This analysis did not allow a comparison between modalities-the perennial problem of leads to varying conclusions. Davenport et al. [19] , confirming results of previous work [21] , showed better comparing the delivered dose of a continuous therapy to that of an intermittent therapy remained. Other haemodynamic tolerance in unstable patients with hepatic failure during the first 5 h of CAVH/CAVHD problems, specific to the ICU ARF population, further confuse the issue. treatment than in 4 h intermittent haemofiltration sessions. Oxygen delivery and consumption also appeared Clearance-based methods, such as the Kt/V, are primed with potential problems in this setting. Firstly, to be better maintained with the continuous therapies. Although prospective, this study was not fully random-'Kt/V' translates quite differently depending on the continuity of therapy [33] . The weekly Kt/V of a ized, with candidates with raised intracranial pressure being diverted to the CRRT arm (whether full ran-continuous modality is equivalent to the ratio of solute mass removed per week to the solute mass actually domization would have actually changed the results is open to debate). Misset and co-workers, in a random-present within the patient. At steady state, the plasma solute concentration will remain static with removal ized, cross-over study [26 ] , compared haemodynamic tolerance during 24 h periods of CAVH and 24 h matching generation. The Kt/V of an intermittent modality is conceptually different, having to take periods encompassing a 4 h IHD treatment. Each period was separated by a 24 h wash-out. No difference account (using a logarithmic function) of declining efficiency of solute removal over the course of a dialysis could be found in any haemodynamic parameter (MAP, dose of adrenergic drugs employed or change session caused by falling solute concentrations and hence falling transmembrane solute concentration grain body weight). There was, however, a high drop-out rate (31%), mostly related to early deaths, which could dients. This is compounded by the effects of recirculation and compartmental solute disequilibrium [33] . potentially have selected out patients who might have shown a modality-specific haemodynamic response. In Broadly speaking, the less intermittent (i.e. the more continuous) a therapy is, the lower the Kt/V needed addition, discrete hypotensive episodes were not reported and may have been missed if not picked up to remove a given quantity of solute. Cumulative Kt/Vs can represent quite different quantities of solute in the course of regular monitoring. Other comparative studies, although showing greater haemodynamic removed in intermittent schedules of differing frequencies [8] . instability in intermittent therapy, have been hampered by their retrospective and non-randomized nature
The second potential stumbling block with clearance-based methods, the wide, intra-individual vari- [27, 28] .
A prospective analysis of all intermittent treatments ation in G makes both inter-and intra-individual comparisons even less tenable-adequate solute performed at a single institution showed that only 7.9% of treatments were terminated prematurely [29] . removal in one dialysis session may be inadequate at the next due to an increase in G. Looked at another Just over half of these terminations (4.9% of the total ) were due to hypotension. The authors concluded that way, a given value of Kt/V may reflect widely differing amounts of solute removal in different dialysis sessions contemporary techniques of intermittent treatment could provide 'excellent hemodynamic stability', in the same patient and may not reflect so much on treatment efficiency as prescription efficiency. A high although no indication of intradialytic hypotension,
an issue with, for instance, anti-inflammatory cytokines Even the three BUN method (pre-/post-/pre-∞) of formal UKM may not capture the rapid fluxes in G in whom endogenous turnover may far outstrip exogenous removal [36 ] but may be important for those that may occur.
The third drawback of blood-side kinetics is the use substances with a low endogenous turnover or those derived from exogenous sources-nutrients and drugs of a single pool model. An expanded urea space (due to fluid overload) and diminished perfusion of urea-for instance. Poor diffusive clearance of b 2 M, even with a high flux membrane such as the AN69, has rich tissues (due to peripheral vasoconstriction) can cause potentially huge post-dialysis urea rebound, recently been shown [37] , emphasizing the role of convective removal of middle molecules, especially at resulting in significant overestimations of delivered dialysis dose.
higher ultrafiltration rates when the solute effluent/ plasma ratio may actually increase [37] . Although not Theoretically, continuous forms of therapy should be able to provide greater low and middle molecular necessarily a modality-specific issue, the more frequent use of convective techniques in CRRT could suggest a weight solute removal than intermittent modes [7, 8] [20] was prospective and none were fully ting and subsequent down-time may be the most frequent problem encountered with CRRT [32]), and randomized. Renal recovery was only addressed in two studies with no definite conclusions being drawn. simply comparing serum solute levels at initiation of renal replacement therapy to those 24 h later [22, 23] .
Whilst acknowledging their methodological problems, the authors combined all 15 studies for further analysis. Clark et al. [7, 8] developed elegant mathematical models, based on real patients receiving CRRT, to No clear benefit of CRRT could be found despite adjustment for co-morbidities. assess theoretical delivered dose in continuous and intermittent therapies. They found that at least five, What is the rô le of severity scoring systems in predicting outcome in our population? simulated, intermittent treatments were needed per week for the peak (pre-IHD) BUN to equal the General severity scoring systems such as the APACHE II, used as predictive models in the context TAC urea in the real CRRT group [7] . Keshaviah's peak concentration hypothesis [35] was invoked whereby of ARF, can underestimate risk of death [12, 40] . In contrast, ARF-specific risk models generally have a the peak toxin concentration is held to be more important than its time averaged concentration in terms of much closer fit between predicted and actual mortality AP 2 /AP 1 ratio (see above) to be highly discriminatory, has received increasing attention and has been mooted as a potential advantage over IHD. A recent editorial with higher ratios predicting poor survival [15] . Even ARF-specific models with good performance within in this journal [36 ] dampens enthusiasm, noting both a lack of consistent human data as well as the disparity their institution may perform suboptimally outside of it [32, 40] suggesting that they describe patient groups between the high endogenous turnover of these mediators and their negligible extracorporeal clearance.
rather than the individual outcome expectation [32] . The Cleveland Clinic ICU ARF scoring system, The role of middle molecular toxicity in ARF is based on prospectively collected data on 512 dialysis-(bicarbonate) were consistent across modalities.
Dialysis dose was prescribed to produce a 3.6 weekly requiring ICU ARF patients, has been prospectively validated within our institution [32] . We are using a Kt/V (with its attendant problems for cross-modality comparisons) but subsequently adjusted using the novel, web-based technique to test both the Cleveland Clinic Foundation scoring system and other models on TAC urea . The two groups were similar in terms of age, gender, illness severity, and pre-therapy BUN and a global basis, allowing individual physicians to generate severity scores based upon anonymised patient creatinine. No significant differences were found in any parameter. There were trends towards a lower TAC urea data. Although necessarily relying on the individual to enter as complete a data set as possible from any and higher renal recovery rates in the CVVHD group, but with longer ICU stays and a higher mortality. number of their ICU ARF cohort, the website (http://www.bio.ri.ccf.org/ARF/) will hopefully pro-
The need for large scale, multicentre study seems pressing but validated ICU ARF patient severity scores vide a unique and expanding 'living' database that may provide the framework for more rigorous cyber-and unifying dosing methodologies seem pivotal to any future approach. Until we know both 'who' and space-based interactions.
'what' we are comparing, the scope of further study will indeed be limited and this particular Gordian
The future knot, although teased at, will remain uncut.
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